Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kent E Wallner

Showing results (51-60 of 114) with videos related to

Pageof 12
Sort By:
Journal of Contemporary Brachytherapy|December 6, 2017
Does supplemental external beam radiation therapy impact urinary, bowel, and erectile function following permanent prostate brachytherapy?: results of two prospective randomized trialsGregory S Merrick, Ava Tennant, Kent E Wallner, et al.
American Journal of Clinical Oncology|December 20, 2007
Obesity is not predictive of overall survival following permanent prostate brachytherapyGregory S Merrick, Robert W Galbreath, Wayne M Butler, et al.
International Journal of Radiation Oncology, Biology, Physics|May 10, 2006
Androgen-deprivation therapy does not impact cause-specific or overall survival after permanent prostate brachytherapyGregory S Merrick, Wayne M Butler, Kent E Wallner, et al.
BJU International|February 12, 2005
Brachytherapy-related dysuriaGregory S Merrick, Wayne M Butler, Kent E Wallner, et al.
Cancer Journal (Sudbury, Mass.)|August 2, 2005
The impact of primary Gleason grade on biochemical outcome following brachytherapy for hormone-naive Gleason score 7 prostate cancerGregory S Merrick, Wayne M Butler, Kent E Wallner, et al.
Urology|July 18, 2006
Efficacy of neoadjuvant bicalutamide and dutasteride as a cytoreductive regimen before prostate brachytherapyGregory S Merrick, Wayne M Butler, Kent E Wallner, et al.
Brachytherapy|December 31, 2010
The correlation between annular treatment margins and biochemical failure in prostate brachytherapy patients with optimized intraprostatic dosimetryNathan Bittner, Gregory S Merrick, Wayne M Butler, et al.
Brachytherapy|April 6, 2004
Prostate-specific antigen (PSA) velocity and benign prostate hypertrophy predict for PSA spikes following prostate brachytherapyGregory S Merrick, Wayne M Butler, Kent E Wallner, et al.
Brachytherapy|March 23, 2012
Long-term outcome for very high-risk prostate cancer treated primarily with a triple modality approach to include permanent interstitial brachytherapyNathan Bittner, Gregory S Merrick, Wayne M Butler, et al.
BJU International|March 6, 2010
Relationship between prostate cancer mortality and number of unfavourable risk factors in men treated with definitive brachytherapyAl V Taira, Gregory S Merrick, Robert W Galbreath, et al.
Pageof 12

Showing results (51-60 of 114) with videos related to

Sort By:
Pageof 12
Journal of Contemporary Brachytherapy|December 6, 2017
Does supplemental external beam radiation therapy impact urinary, bowel, and erectile function following permanent prostate brachytherapy?: results of two prospective randomized trialsGregory S Merrick, Ava Tennant, Kent E Wallner, et al.
American Journal of Clinical Oncology|December 20, 2007
Obesity is not predictive of overall survival following permanent prostate brachytherapyGregory S Merrick, Robert W Galbreath, Wayne M Butler, et al.
International Journal of Radiation Oncology, Biology, Physics|May 10, 2006
Androgen-deprivation therapy does not impact cause-specific or overall survival after permanent prostate brachytherapyGregory S Merrick, Wayne M Butler, Kent E Wallner, et al.
BJU International|February 12, 2005
Brachytherapy-related dysuriaGregory S Merrick, Wayne M Butler, Kent E Wallner, et al.
Cancer Journal (Sudbury, Mass.)|August 2, 2005
The impact of primary Gleason grade on biochemical outcome following brachytherapy for hormone-naive Gleason score 7 prostate cancerGregory S Merrick, Wayne M Butler, Kent E Wallner, et al.
Urology|July 18, 2006
Efficacy of neoadjuvant bicalutamide and dutasteride as a cytoreductive regimen before prostate brachytherapyGregory S Merrick, Wayne M Butler, Kent E Wallner, et al.
Brachytherapy|December 31, 2010
The correlation between annular treatment margins and biochemical failure in prostate brachytherapy patients with optimized intraprostatic dosimetryNathan Bittner, Gregory S Merrick, Wayne M Butler, et al.
Brachytherapy|April 6, 2004
Prostate-specific antigen (PSA) velocity and benign prostate hypertrophy predict for PSA spikes following prostate brachytherapyGregory S Merrick, Wayne M Butler, Kent E Wallner, et al.
Brachytherapy|March 23, 2012
Long-term outcome for very high-risk prostate cancer treated primarily with a triple modality approach to include permanent interstitial brachytherapyNathan Bittner, Gregory S Merrick, Wayne M Butler, et al.
BJU International|March 6, 2010
Relationship between prostate cancer mortality and number of unfavourable risk factors in men treated with definitive brachytherapyAl V Taira, Gregory S Merrick, Robert W Galbreath, et al.
Pageof 12